Interference of ATP‐Adenosine Axis by Engineered Biohybrid for Amplifying Immunogenic Cell Death‐Mediated Antitumor Immunotherapy

Immunogenic cell death (ICD) often results in the production and accumulation of adenosine (ADO), a byproduct that negatively impacts the therapeutic effect as well as facilitates tumor development and metastasis. Here, an innovative strategy is elaborately developed to effectively activate ICD while avoiding the generation of immunosuppressive adenosine. Specifically, ZIF‐90, an ATP‐responsive consumer, is synthesized as the core carrier to encapsulate AB680 (CD73 inhibitor) and then coated with an iron‐polyphenol layer to prepare the ICD inducer (AZTF), which is further grafted onto prebiotic bacteria via the esterification reaction to obtain the engineered biohybrid (Bc@AZTF). Particularly, the designed Bc@AZTF can actively enrich in tumor sites and respond to the acidic tumor microenvironment to offload AZTF nanoparticles, which can consume intracellular ATP (iATP) content and simultaneously inhibit the ATP‐adenosine axis to reduce the accumulation of adenosine, thereby alleviating adenosine‐mediated immunosuppression and strikingly amplifying ICD effect. Importantly, the synergy of anti‐PD‐1 (αPD‐1) with Bc@AZTF not only establishes a collaborative antitumor immune network to potentiate effective tumoricidal immunity but also activates long‐lasting immune memory effects to manage tumor recurrence and rechallenge, presenting a new paradigm for ICD treatment combined with adenosine metabolism. An engineered biohybrid (Bc@AZTF) is rationally designed to activate immunogenic cell death (ICD) therapy and impede the production of immunosuppressive adenosine, which can establish a collaborative antitumor immune network to potentiate effective tumoricidal immunity and activate the enduring immunological memory to manage tumor recurrence and rechallenge, thereby amplifying ICD‐mediated antitumor immunotherapy.